Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

AMVUTTRA

VUTRISIRAN SODIUM

Standard Dose
EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview AMVUTTRA is listed in Drugs@FDA under application 215515 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient VUTRISIRAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2025-03-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMVUTTRA is listed in Drugs@FDA under application 215515 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient VUTRISIRAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2025-03-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.